Relief of signs and symptoms of osteoarthritis and rheumatoid arthritis. Relief of the signs and symptoms of pauciarticular or polyarticular course juvenile rheumatoid arthritis (JRA) in patients 2 yr of age and older.
Treatment of ankylosing spondylitis, pain, and acute shoulder pain.
CV: Angina pectoris, arrhythmia, cardiac failure, hypertension, hypotension, MI, palpitation, tachycardia, vasculitis (less than 2%). CNS: Headache (8%); dizziness, insomnia (4%); abnormal dreaming, anxiety, confusion, convulsions, depression, fatigue, increased appetite, nervousness, paresthesia, somnolence, tremor, vertigo, (less than 2%). DERM: Rash (3%); pruritus (2%); alopecia, angioedema, bullous eruption, increased sweating, photosensitivity reaction, urticaria (less than 2%); erythema multiforme, exfoliative dermatitis, Stevens-Johnson syndrome, toxic epidermal necrolysis (postmarketing). EENT: Pharyngitis (3%); abnormal vision, conjunctivitis, taste perversion, tinnitus (less than 2%). GI: Dyspepsia (10%); diarrhea (8%); nausea (7%); dyspeptic signs and symptoms (6%); abdominal pain (5%); constipation, flatulence, vomiting (3%); colitis, dry mouth, duodenal ulcer, eructation, esophagitis, gastric ulcer, gastritis, gastroesophageal reflux, GI hemorrhage, hematemesis, hemorrhagic duodenal ulcer, hemorrhagic gastric ulcer, intestinal perforation, melena, pancreatitis, perforated duodenal ulcer, perforated gastric ulcer, ulcerative stomatitis (less than 2%). GU: UTI (7%); micturition frequency (2%); albuminuria, increased BUN and creatinine, hematuria, renal failure (less than 2%); interstitial nephritis (postmarketing). HEMA/LYMPH: Anemia (4%); leukopenia, purpura, thrombocytopenia (less than 2%); agranulocytosis (postmarketing). HEPA: Increased ALT and AST, bilirubinemia, hepatitis, increased gamma-glutamyl-transferase (less than 2%); jaundice, liver failure (postmarketing). M/N: Dehydration, weight decrease or increase (less than 2%). MUSC: Arthralgia (5%); back pain (3%); joint-related signs and symptoms (2%). RESP: Upper respiratory tract infection (8%); coughing (2%); asthma, bronchospasm, dyspnea (less than 2%). OTHER: Influenza-like symptoms (6%); edema, household accidents, pain (5%); fall (3%); allergic reaction, face edema, fever, hot flushes, malaise, syncope (less than 2%); anaphylactic reactions, including shock (postmarketing).
NSAIDs may cause an increased risk of serious CV thrombotic events, MI, and stroke that can be fatal. Risk may be increased with duration of use and in patients with CV disease, or risk factors for CV disease. Use lowest effective dose for shortest duration possible. Meloxicam is contraindicated for treatment of perioperative pain in the setting of CABG surgery.
NSAIDs cause an increased risk of serious GI adverse reactions, including bleeding, ulceration, and perforation of the stomach or intestines that can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients are at greater risk for serious GI events.